KR20150140418A - 치환된 헤테로사이클 융합 감마-카볼라인 고체 - Google Patents

치환된 헤테로사이클 융합 감마-카볼라인 고체 Download PDF

Info

Publication number
KR20150140418A
KR20150140418A KR1020157034267A KR20157034267A KR20150140418A KR 20150140418 A KR20150140418 A KR 20150140418A KR 1020157034267 A KR1020157034267 A KR 1020157034267A KR 20157034267 A KR20157034267 A KR 20157034267A KR 20150140418 A KR20150140418 A KR 20150140418A
Authority
KR
South Korea
Prior art keywords
salt crystals
salt
disorder
crystals
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157034267A
Other languages
English (en)
Korean (ko)
Inventor
로렌스 피. 웨노글
존 토메쉬
Original Assignee
인트라-셀룰라 써래피스, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150140418(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 인트라-셀룰라 써래피스, 인코퍼레이티드. filed Critical 인트라-셀룰라 써래피스, 인코퍼레이티드.
Publication of KR20150140418A publication Critical patent/KR20150140418A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
KR1020157034267A 2008-03-12 2009-03-12 치환된 헤테로사이클 융합 감마-카볼라인 고체 Withdrawn KR20150140418A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3606908P 2008-03-12 2008-03-12
US61/036,069 2008-03-12
PCT/US2009/001608 WO2009114181A2 (en) 2008-03-12 2009-03-12 Substituted heterocycle fused gamma-carbolines solid

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107022312A Division KR101610977B1 (ko) 2008-03-12 2009-03-12 치환된 헤테로사이클 융합 감마-카볼라인 고체

Publications (1)

Publication Number Publication Date
KR20150140418A true KR20150140418A (ko) 2015-12-15

Family

ID=41065729

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157034267A Withdrawn KR20150140418A (ko) 2008-03-12 2009-03-12 치환된 헤테로사이클 융합 감마-카볼라인 고체
KR1020107022312A Active KR101610977B1 (ko) 2008-03-12 2009-03-12 치환된 헤테로사이클 융합 감마-카볼라인 고체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107022312A Active KR101610977B1 (ko) 2008-03-12 2009-03-12 치환된 헤테로사이클 융합 감마-카볼라인 고체

Country Status (16)

Country Link
US (4) US8648077B2 (https=)
EP (1) EP2262505B1 (https=)
JP (1) JP5611846B2 (https=)
KR (2) KR20150140418A (https=)
CN (2) CN105237536A (https=)
AU (1) AU2009223701B2 (https=)
CA (1) CA2716730C (https=)
DK (1) DK2262505T3 (https=)
ES (1) ES2530090T3 (https=)
HR (1) HRP20141178T1 (https=)
IL (3) IL207772A0 (https=)
MX (2) MX347257B (https=)
PL (1) PL2262505T3 (https=)
PT (1) PT2262505E (https=)
SI (1) SI2262505T1 (https=)
WO (1) WO2009114181A2 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102065319B1 (ko) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
JP5611846B2 (ja) 2008-03-12 2014-10-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 置換ヘテロ環縮合ガンマ−カルボリン類固体
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
US9107696B2 (en) * 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
EP2560676B8 (en) 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
IL305990B2 (en) 2013-12-03 2025-12-01 Intra Cellular Therapies Inc Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
RU2016143091A (ru) 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
MX365969B (es) 2014-04-04 2019-06-21 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
CN108883111B (zh) 2016-01-26 2021-10-08 细胞内治疗公司 有机化合物
PL3407889T3 (pl) 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
JP2019513143A (ja) * 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP4001281A1 (en) 2016-08-09 2022-05-25 Teva Pharmaceuticals International GmbH Solid state forms of lumateperone ditosylate salt and preparation thereof
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
JP2020513023A (ja) 2017-04-10 2020-04-30 ドクター・レディーズ・ラボラトリーズ・リミテッド ルマテペロンｐ−トシラートの非晶質形態および固体分散体
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP7223742B2 (ja) 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
US11655251B2 (en) 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
CN109867674A (zh) * 2017-12-05 2019-06-11 上海度德医药科技有限公司 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2019183546A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
IL321985A (en) * 2018-06-06 2025-09-01 Intra Cellular Therapies Inc New salts and crystals
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
CA3106447A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US11806311B2 (en) 2018-06-21 2023-11-07 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND PROCESSES
CA3108558A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CN112584837A (zh) * 2018-08-31 2021-03-30 细胞内治疗公司 新方法
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
JP7637616B2 (ja) 2018-09-07 2025-02-28 アクエスティブ セラピューティクス インコーポレイテッド 厳密な活性剤溶解プロファイルを有する口腔用フィルム組成物及び剤形
US20220024924A1 (en) 2018-11-27 2022-01-27 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
EP3898580A4 (en) 2018-12-17 2022-08-10 Intra-Cellular Therapies, Inc. SYNTHESIS OF CONDENSED GAMMA-CARBOLINES WITH SUBSTITUTED HETEROCYCLE
IL283963B2 (en) 2018-12-17 2025-01-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
BR112021011792A2 (pt) 2018-12-17 2021-08-31 Intra-Cellular Therapies, Inc. Composto orgânico
US12195463B2 (en) 2018-12-21 2025-01-14 Intra-Cellular Therapies, Inc. Organic compounds
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
WO2020182978A1 (en) 2019-03-13 2020-09-17 Sandoz Ag Crystalline salt of a 5-ht2a receptor antagonist
JP7673040B2 (ja) 2019-07-07 2025-05-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
BR112022008294A2 (pt) 2019-11-01 2022-07-26 Aquestive Therapeutics Inc Composições de profármaco e métodos de tratamento
WO2021097247A1 (en) 2019-11-14 2021-05-20 Aquestive Therapeutics, Inc. Multimodal compositions and methods of treatment
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
EP4076461B1 (en) 2019-12-19 2026-01-28 Intra-Cellular Therapies, Inc. Lumateperone for use in schizophrenia treatment
WO2022155544A1 (en) 2021-01-15 2022-07-21 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
CA3210706A1 (en) 2021-03-09 2022-09-15 Alexander Mark Schobel Dosage forms having equivalent biocomparable profiles
IL308750A (en) * 2021-06-07 2024-01-01 Intra Cellular Therapies Inc Novel salts and crystals
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
JP2025521115A (ja) 2022-05-18 2025-07-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
TWI902035B (zh) * 2022-10-26 2025-10-21 大陸商上海樞境生物科技有限公司 一種雜環取代的稠合γ-咔啉類衍生物的甲磺酸鹽、晶型及其製備方法和應用
JP2026502895A (ja) 2022-12-30 2026-01-27 イントラ－セルラー・セラピーズ・インコーポレイテッド セロトニン５－ｈｔ２ａ受容体に作用する複素環縮合ガンマ－カルボリン
EP4665344A1 (en) 2023-02-17 2025-12-24 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025240804A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices and methods
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713471B1 (en) * 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) * 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
MXPA01012969A (es) 1999-06-15 2003-10-14 Bristol Myers Squibb Pharma Co Gamma-carbolinas fusionadas de heterociclo sustituido.
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2004259741A1 (en) * 2003-07-21 2005-02-03 Smithkline Beecham Corporation (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
KR102065319B1 (ko) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
JP5611846B2 (ja) 2008-03-12 2014-10-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 置換ヘテロ環縮合ガンマ−カルボリン類固体
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
EP2560676B8 (en) 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek

Also Published As

Publication number Publication date
JP2011513485A (ja) 2011-04-28
ES2530090T3 (es) 2015-02-26
CN105237536A (zh) 2016-01-13
US20140323491A1 (en) 2014-10-30
DK2262505T3 (en) 2015-01-05
MX2010010024A (es) 2010-11-09
US20110112105A1 (en) 2011-05-12
US9586960B2 (en) 2017-03-07
KR101610977B1 (ko) 2016-04-08
CA2716730A1 (en) 2009-09-17
AU2009223701B2 (en) 2015-04-16
EP2262505A4 (en) 2012-03-07
USRE48825E1 (en) 2021-11-23
EP2262505A2 (en) 2010-12-22
AU2009223701A1 (en) 2009-09-17
IL207772A0 (en) 2010-12-30
IL289706A (en) 2022-03-01
KR20100122948A (ko) 2010-11-23
HK1152231A1 (en) 2012-02-24
US20160194325A1 (en) 2016-07-07
PL2262505T3 (pl) 2015-04-30
HRP20141178T1 (hr) 2015-04-10
WO2009114181A2 (en) 2009-09-17
WO2009114181A3 (en) 2009-12-30
EP2262505B1 (en) 2014-09-10
US9199995B2 (en) 2015-12-01
CN102046175A (zh) 2011-05-04
PT2262505E (pt) 2014-12-16
CN102046175B (zh) 2015-08-12
CA2716730C (en) 2017-05-16
IL263338A (en) 2018-12-31
JP5611846B2 (ja) 2014-10-22
SI2262505T1 (sl) 2015-03-31
MX347257B (es) 2017-04-20
US8648077B2 (en) 2014-02-11

Similar Documents

Publication Publication Date Title
KR101610977B1 (ko) 치환된 헤테로사이클 융합 감마-카볼라인 고체
EP2785702B1 (en) Crystalline dapagliflozin hydrate
KR101787784B1 (ko) 3－（2,6―디클로로―3,5―디메톡시―페닐）－1－｛6－［4－（4－에틸－피페라진－1－일）－페닐아미노］－피리미딘－4－일｝－1－메틸－우레아의 결정질 형태 및 그의 염
EP2411394B1 (en) Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
AU2010283689A1 (en) Crystalline compound of 7-[(3R)-3-amino-1-oxo-4-(2, 4, 5-trifluorphenyl)butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluormethyl)-1, 2, 4 -triazolo[4,3-a]pyrazine
CA2993356C (en) Processes for preparing an fgfr inhibitor
CN119212696A (zh) [2-(1h-吲哚-3-基)-1h-咪唑-4-基](3,4,5-三甲氧基)甲酮和其盐的多晶型物
EA017483B1 (ru) Стабильная кристаллическая соль 1-азабицикло[2.2.2]окт-3-илового сложного эфира (r)-3-фторфенил-3,4,5-трифторбензилкарбаминовой кислоты
US9127018B2 (en) Solid forms of ortataxel
KR20120053027A (ko) 페소테로딘 푸마레이트 및 페소테로딘 염기의 결정형
HK1152231B (en) Substituted heterocycle fused gamma-carbolines solid
AU2015204363A1 (en) Substituted heterocycle fused gamma-carbolines solid
WO2016112879A1 (en) CRYSTALLINE MODIFICATION 2 OF (3/R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-6,8-DIHYDRO-5H-[1,2,4]TRIAZOLO[4,3-α]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE L-TARTRATE
TW201636346A (zh) 二－匹多莫德苄乙二胺及其固體型

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151201

Application number text: 1020107022312

Filing date: 20101006

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151230

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160630

Patent event code: PE09021S01D

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20160905

WITB Written withdrawal of application